WINTON GROUP Ltd trimmed its stake in Vericel Corp (NASDAQ:VCEL) by 34.4% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 10,927 shares of the biotechnology company’s stock after selling 5,721 shares during the quarter. WINTON GROUP Ltd’s holdings in Vericel were worth $206,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can bought a new stake in Vericel in the fourth quarter valued at $78,000. Bank of New York Mellon Corp lifted its stake in Vericel by 85.7% in the fourth quarter. Bank of New York Mellon Corp now owns 245,419 shares of the biotechnology company’s stock valued at $4,270,000 after buying an additional 113,270 shares during the last quarter. Pearl River Capital LLC bought a new stake in Vericel in the first quarter valued at $72,000. American Century Companies Inc. bought a new stake in Vericel in the fourth quarter valued at $2,275,000. Finally, Principal Financial Group Inc. lifted its stake in Vericel by 12.4% in the fourth quarter. Principal Financial Group Inc. now owns 21,484 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 2,362 shares during the last quarter. Institutional investors own 86.59% of the company’s stock.
VCEL has been the topic of a number of recent research reports. Oppenheimer raised their target price on Vericel from $23.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. BidaskClub upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Zacks Investment Research upgraded Vericel from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $22.98.
Shares of VCEL traded down $0.82 during trading hours on Friday, reaching $18.54. 386,846 shares of the company’s stock traded hands, compared to its average volume of 350,809. The company has a market cap of $850.12 million, a price-to-earnings ratio of -132.43 and a beta of 2.76. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.47 and a quick ratio of 8.16. Vericel Corp has a twelve month low of $9.70 and a twelve month high of $21.00. The stock has a fifty day simple moving average of $18.67.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $21.81 million for the quarter, compared to analyst estimates of $22.51 million. Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period last year, the company earned ($0.21) earnings per share. On average, research analysts forecast that Vericel Corp will post -0.19 earnings per share for the current fiscal year.
In other news, CFO Gerard J. Michel sold 17,500 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $17.02, for a total transaction of $297,850.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Gerard J. Michel sold 17,000 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $19.68, for a total value of $334,560.00. The disclosure for this sale can be found here. Insiders have sold 52,000 shares of company stock worth $905,760 over the last three months. Corporate insiders own 4.50% of the company’s stock.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.